ArticleBMC cancer2025

Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU).

Katsuyuki Sakanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.